SMMT Stock Analysis: Buy, Sell, or Hold?
SMMT - Summit Therapeutics Inc. Common Stock
$14.06
-0.42 (-2.90%)
▼
5d:
-15.1%
30d:
-19.61%
90d:
-24.57%
HOLD
MODERATE Confidence
Last Updated: February 2, 2026
Earnings: Feb 23, 2026
19d
Get Alerted When SMMT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
3 traders called SMMT this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SMMT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: SMMT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: SMMT is currently trading at $14.06, which is considered oversold relative to its 30-day fair value range of $15.76 to $18.37.
Technical Outlook: Technically, SMMT is in a strong uptrend. The price is currently testing key support at $14.20. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SMMT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $33.05 (+135.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SMMT is in a strong uptrend. The price is currently testing key support at $14.20. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SMMT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $33.05 (+135.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$15.76 -
$18.37
Company Quality Score
34/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 135.1% below Wall St target ($33.05)
- CAUTION: 5-day price weakness (-15.1%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$15.76 -
$18.37
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$14.20
Resistance Level
$17.98
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-18.96
Wall Street Target
$33.05
(+135.1%)
Revenue Growth (YoY)
-100.0%
Last updated: February 03, 2026 5:55 AM ET
Data refreshes hourly during market hours. Next update: 6:55 AM
Data refreshes hourly during market hours. Next update: 6:55 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SMMT showing a specific setup today?
Insider Activity (6 Months)
7
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Mahkam Zanganeh
BUY
26680 shares
2025-10-21
Robert W Duggan
BUY
26680 shares
2025-10-21
Yu Xia
BUY
533617 shares
2025-10-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$66 | 58 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$93 | 60 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$108 | 55 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$34 | 51 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$71 | 60 HOLD |
